Last reviewed · How we verify
CBMNC
At a glance
| Generic name | CBMNC |
|---|---|
| Sponsor | yangjie |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms (PHASE1)
- Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy (PHASE1)
- Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBMNC CI brief — competitive landscape report
- CBMNC updates RSS · CI watch RSS
- yangjie portfolio CI